United States Securities and Exchange Commission · EDGAR
Accession 0001955277-26-000001
Myosana Therapeutics, Inc.
Nature of amendmentAdding 2025 financials and extending
A
The Offering
as disclosed in this filing
Other (Simple Agreement for Future Equity (SAFE))
$1.00
$50,000
$1,235,000
April 30, 2027
320 days remaining
$0max $1,235,000
Target is 4% of the maximum. Over-subscriptions accepted.
B
Financial Condition
two fiscal years, as filed
Pre-revenueBurn decreasingDebt / assets 1%0 employees
| Line item | Most recent FY | Prior FY | Δ |
|---|
| Revenue | 0 | 0 | — |
| Cost of goods sold | 0 | 0 | — |
| Net income | (1,219,557) | (1,573,691) | ▲ burn |
| Total assets | 944,981 | 2,229,084 | ▼ 58% |
| Cash & equivalents | 37,467 | 695,125 | ▼ 95% |
| Accounts receivable | 5,191 | 36,241 | ▼ 86% |
| Short-term debt | 9,021 | 105,558 | ▼ 91% |
| Long-term debt | 0 | 0 | — |
| Taxes paid | 0 | 0 | — |
Figures in USD as reported by the issuer. Securities offered in all 50 states.
C
Campaign Timeline
file 020-36574 · all filings under this campaign
Loading campaign history…